Representation of women and racial minorities in SGLT2 inhibitors and heart failure clinical trials

This publication has 70 references indexed in Scilit:

• DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome — A 3-month, multicenter, randomized controlled clinical trial
  European Journal of Clinical Pharmacology, 2024
• Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( DAPA‐VO ₂ ): a randomized clinical trial
  European Journal of Heart Failure, 2022
• Empagliflozin Reduces Markers of Acute Kidney Injury in Patients with Acute Decompensated Heart Failure
  ESC Heart Failure, 2022
• Gender and Disparity in First Authorship in Cardiology Randomized Clinical Trials
  JAMA Network Open, 2021
• Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review
  European Journal of Heart Failure, 2020
• The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study
  Diabetes/Metabolism Research and Reviews, 2020
• Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial (CANDLE)
  ESC Heart Failure, 2020
• Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)
  European Journal of Heart Failure, 2020
• Underrepresentation of Women, Elderly Patients, and Racial Minorities in the Randomized Trials Used for Cardiovascular Guidelines
  JAMA Internal Medicine, 2014
• The success of recruiting minorities, women, and elderly into a randomized controlled effectiveness trial
  Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2008